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years PFS was 79% and 40%, respectively. Median time to 
progression and median OS were 18 months and 24 months, 
respectively. Local control was 93% at 1 year and 64% at 2 
years. Local progression occurred in 4 metastases (14%). 
Overall, acute toxicity occurred in 18% (4/22) of patients; 
two patients experienced grade 2 pneumonitis. Grade 1-2 
late toxicity occurred in 50% of patients. No grade≥3 
toxicities were recorded. 
Conclusions: Local treatment is a feasible and well-tolerated 
treatment for oligometastatic NSCLC patients. Ablative RT 
has a potential role in the local control of the lung 
metastases and in the management of well-selectedstage IV 
NSCLC patients in increasing quality of life and survival. 
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Purpose/Objective: The aim of this study was investigate 
whether the standardized uptake value (SUV-max) of tumor 
from [18F]-fluoro-2-deoxy-glucose positron emission 
tomography (FDG-PET) was associated with outcome in 
patients with non-small-cell lung cancer (NSCLC) treated with 
curative stereotactic body radiotherapy (SBRT). 
Materials and Methods: Between January 2006 and January 
2014, a total of 46 patients with medically inoperable early 
stage NSCLC underwent SBRT. 32/46 (69.57%) and 14/46 
(30.43%) had stage IA and IB, respectively. The treatment 
was administred as 40-50 Gy in 5 fractions; the dose was 
prescribed to the isocenter. Histology was confirmed in 36/46 
(78.26%) patients. All received FDG-PET/computed 
tomography (CT) at the same institution before SBRT, 3-4 
months after the end of SBRT and every 4-6 months 
thereafter. We reviewed the values of the metabolic activity 
of the lung lesion before and after treatment, expressed as 
maximum standardized uptake value (SUV-max) before SBRT 
(SUV-max pre-SBRT), first SUV after SBRT (1st SUV-post-SBRT) 
and the lowest value of SUV in the longitudinal follow-up 
(SUV-nadir). The values were then analyzed with Cox 
proportional hazards regression to assess whether the 
metabolic activity could has a predictive value in treatment 
outcome: local failure (LF), mediastinal failure (MF), 
systemic progression (SP), overall survival (OS) and cancer 
specific survival (CS). 
Results: Median follow-up was 20.5 months (range 4 – 91) for 
whole group. The median SUVmax pre-SBRT was 7.70 
(range,1.4-28.9), median 1st SUV post-SBRT was 3.25 (range 
0.0-9), median SUV-nadir was 1.90 (range 0.0-8). Local 
complete and partial response was observed in 37/46 
(80.43%) and 9/46 (19.57%) patients, respectively. Kaplan-
Meier three-years LF, MF, SP were 18.7%, 5% and 5%, 
respectively. Three-years OS and CS were 67.7% and 82.1%, 
respectively. We have found similar rates of response in 
terms of complete and partial response, even if the SUVmax 
before treatment was higher or lower than the median value 
in our study (7.70). In univariate analysis, SUVmax pre-SBRT, 
1st SUV-post-SBRT and SUV-nadir did not predict for LF, MF, 
SP, OS and CS.  
Conclusions: SBRT was an effective treatment for medically 
inoperable early-stage NSCLC. On the basis of our results PET 
SUV-max pre-SBRT, 1st SUV-post-SBRT and SUV-nadir did not 
predict for LF, MF, SP, OS and CS. 
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Purpose/Objective: A murine breast cancer xenograft model 
was employed to evaluate inter- and intra-variability of 
various parameters derived from dynamic positron emission 
tomography with [18F]fluorodeoxyglucose as tracer (FDG-
PET). 
Materials and Methods: 17 female athymic nude foxn1/nu 
mice with bila-terally implanted triple-negative basal-like 
ductal carcinoma (MAS98.12) breast cancer xenografts 
underwent a dynamic PET scan over an hour after injection 
of ~10 MBq FDG. Inter-animal data were obtained from the 
entire animal cohort, while intra-animal data were obtained 
fro-m four mice which received an additional scan after one 
or two days. Standardised uptake values (SUVmax, SUVmean and 
SUVmedian) were estimated for all tumours and livers at 
different time points. Tumour uptake was analysed with 
Patlak analysis and a full kinetic two-compartment model for 
estimation of pharmacokinetic parameters. The coefficient of 
variation (CV) was calculated for all PET-derived metrics. 
Results: The CV for SUVmean and SUVmedian was typically 10-20% 
for the tumours, depending on the time post injection and 
group (intra vs inter). The CV for SUVmax was mostly higher at 
all time points p.i. The variability in the pharmacokinetic 
parameters ranged from 23 to almost 150%. 
Conclusions: SUVmean and SUVmedian show less variability than 
SUVmax. Still, pharmacokinetic tumour metrics show much 
greater variability than the SUV based metrics. However, it is 
generally not known which of these metrics that best 
represents cancer aggressiveness and their use may still 
depend on the research questions addressed. 
   
EP-1184   
Hypofractionated simultaneous integrated boost 
radiotherapy after breast-conserving surgery: 3 years 
follow-up 
I. Linares1, I. Tovar1, R. Del Moral1, M. Zurita1, R. Guerrero1, 
P. Vargas2, M. Martínez3, M.A. Gentil1, C. Prieto1, J. Expósito1 
1Hospital Universitario Virgen de las Nieves, Radiation 
Oncology, Granada, Spain  
2Hospital Torrecárdenas, Radiation Oncology, Almería, Spain  
3Complejo Hospitalario de Jaén, Radiation Oncology, Jaén, 
Spain  
3rd ESTRO Forum 2015                                                                                                                                         S643 
 
Purpose/Objective: The scheme of standard radiotherapy for 
breast cancer treatment involves a high total dose in 25 
fractions. However, a decrease in the total dose, together 
with an increase in the dose per fraction (hypofractionation) 
is discussed to be at least as effective as standard treatment. 
The objective of our study is to analyze the results in local 
control, acute and late toxicity and cosmetic outcome in 
patients treated with hypofractionated radiation therapy 
after conservative surgery for breast cancer in our center. 
Materials and Methods: A retrospective analysis of all women 
diagnosed with breast cancer (Stage 0-III) and treated with 
breast-conserving surgery followed by hypofractionated 
scheme from 2006 to 2011. Total dose on mammary gland: 
42.4 Gy to 2.65 Gy / fraction, for a total of 16 sessions with 
concomitant boost to 7.7 Gy (0.48 Gy / fraction). We 
included patients treated with chemotherapy, hormonal 
therapy and trastuzumab. Acute and late toxicities were 
scored according to the Common Terminology Criteria for 
adverse Events version 4.0 and cosmetic outcome were 
assessed during follow-up every three months up to 2 years 
and every six months up to 5 years after radiotherapy.  
Results: We have treated 143 women with hypofractionated 
scheme. After a median follow up of 36 months, the local 
recurrence rate was 1.4%, only 3.5% experienced nodal 
relapse, one patient developed a contralateral breast cancer 
and 6.3% had distant metastases as first event. There was no 
acute toxicity in 28.4% of cases, being the most frequent 
grade 1 radiodermatitis (61.1%). Regarding late toxicity, this 
was not observed in 65.6%, being grade 1 fibrosis in the 
treated area the most common. The cosmetic outcome was 
good or excellent in 90% of patients treated. At the end of 
the study, 83.8% remained alive without disease, 7% alive 
with disease, 4.9% exitus due to tumor and 4.2% were died 
due to other causes. 
Conclusions: The hipofractionated scheme after conservative 
surgery in breast cancer provides a good control of the 
disease without causing excessive toxicity and providing good 
cosmetic outcomes. Similar results to standard treatment can 
be obtained with a significant reduction in overall treatment 
time. 
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Purpose/Objective: Early breast cancer treated with breast 
conservative therapy (BCT), usually has a good prognosis. 
Recommended target field of RT field is whole breast. 
However, added to the results from MA.20 about regional 
nodal irradiation (RNI) to patients with pN1 status, EORTC 
22922/10925 reported the benefit of RNI for overall survival 
including internal mammary and medial supraclavicular 
lymph node chain especially in tumors situated in medial 
(=inner/central) site without axillary lymph node metastasis. 
Based on our long term date specifically focused on tumor 
site, we assessed the possible utilization of RNI for 
application guideline of breast cancer in Japan. 
Materials and Methods: A total number of patients who were 
treated with BCT are 1200 in our institution. Patients with 
simultaneous bilateral breast cancer and non-invasive breast 
cancer were excluded. Cases with RNI were also excluded. 
1079 cases out of 1200 treated with BCT until December 2012 
were analyzed. 
Median age at diagnosis is 53 years (range: 25-85). Major 
histological type is invasive ductal cancer (93.4%). Tumor 
sizes of origin was in T1; 65.0%, T2; 32.6%, and T3; 1.1%. 
Positive lymph node metastasis was seen in 24.7%. 37.6% of 
patients received chemotherapy, and 73.3% underwent 
hormone therapy. All patients were treated with 
postoperative whole breast RT, in which 37.8% received boost 
RT of 10-14Gy. 
Results: Median follow up period was 120 months (range: 4-
300). A number of tumors located in inner site was 393 
(36.8%), and a number of tumors in outer site was 676 
(63.2%). According to EORTC trial, centrally situated cases 
were regarded as inner cases at the analysis. Ten year overall 
survival rate was favorable (90.1% at inner site and 92.7% at 
outer site (p=0.189)), local recurrence free survival (LRFS) at 
inner/outer site were 90.1%/93.7% (p=0.79), distant 
metastasis free survival (DMFS) were 88.4%/90.1% (p=0.594), 
and disease free survival (DFS) were 72.9%/79.4% (p=0.03) 
respectively. Only DFS was significantly better in outer 
group. 
In cases with positive nodes, LRFS, DMFS, and DFS were not 
significantly different between inner and outer sites. Notably 
in cases with negative nodes, LRFS/DFS/OS of inner situated 
cases were statistically significantly worse. 
Conclusions: In current clinical practice, the whole breast RT 
is recommended to patients with inner situated tumors, 
however, especially in the patients with negative nodes, RNI 
should be considered as a state of the art strategy. 
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Purpose/Objective: Neoadjuvant systemic therapy (NAST) in 
breast cancer potentially down-stages disease, thereby 
posing challenges to the standard indications for nodal 
irradiation. We assessed the pattern of NAST utilization in our 
province and its effect on the recommendation for nodal 
radiotherapy (RT). 
Materials and Methods: Of the 11,628 patients with stages I 
to III breast cancer from 2007-2012, 603 patients (5.2%) were 
treated with NAST. Data from our provincial database were 
obtained to determine relationships between NAST use and 
nodal irradiation. 
